Compounds > safinamide
Page last updated: 2024-09-03

safinamide and Parkinsonian Disorders

safinamide has been researched along with Parkinsonian Disorders in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (60.00)24.3611
2020's2 (40.00)2.80

Authors

AuthorsStudies
Brugnoli, A; Caccia, C; Keywood, C; Melloni, E; Morari, M; Novello, S; Padoani, G; Pisanò, CA; Vailati, S1
Bastioli, G; Caccia, C; Calabresi, P; Cardinale, A; Ghiglieri, V; Keywood, C; Mazzocchetti, P; Melloni, E; Mosci, P; Padoani, G; Picconi, B; Sciaccaluga, M; Tozzi, A; Vailati, S1
Di Paolo, T; Grégoire, L; Jourdain, VA; Roach, A; Townsend, M1
Mullali, G; Piers, T; Pocock, JM; Roach, A; Sadeghian, M; Smith, KJ1
Collins-Praino, LE; Lobianco, C; Podurgiel, S; Randall, PA; Roach, A; Salamone, JD; Yohn, S1

Other Studies

5 other study(ies) available for safinamide and Parkinsonian Disorders

ArticleYear
Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease.
    Neuropharmacology, 2020, 05-01, Volume: 167

    Topics: Alanine; Animals; Benzylamines; Excitatory Amino Acid Antagonists; Glutamic Acid; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley

2020
Effects of safinamide on the glutamatergic striatal network in experimental Parkinson's disease.
    Neuropharmacology, 2020, 06-15, Volume: 170

    Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Corpus Striatum; Dose-Response Relationship, Drug; Excitatory Postsynaptic Potentials; Glutamic Acid; Levodopa; Male; Nerve Net; Organ Culture Techniques; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar

2020
Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys.
    Parkinsonism & related disorders, 2013, Volume: 19, Issue:5

    Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Dose-Response Relationship, Drug; Drug Synergism; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Treatment Outcome

2013
Neuroprotection by safinamide in the 6-hydroxydopamine model of Parkinson's disease.
    Neuropathology and applied neurobiology, 2016, Volume: 42, Issue:5

    Topics: Alanine; Animals; Benzylamines; Dopaminergic Neurons; Male; Microglia; Nerve Degeneration; Neuroprotective Agents; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley

2016
Tremorolytic effects of safinamide in animal models of drug-induced parkinsonian tremor.
    Pharmacology, biochemistry, and behavior, 2013, Volume: 105

    Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Dopamine Agonists; Locomotion; Male; Muscarinic Agonists; Parkinsonian Disorders; Pilocarpine; Rats; Rats, Sprague-Dawley; Tremor

2013